NGDF levels in the blood were found to be significantly elevated in patients with a variety of neurodegenerative diseases and disorders.
So far, there is no clinically validated biomarker for neurodegenerative diseases.
An in vitro diagnostic kit for measuring the NGDF level in blood will be available for clinical trial by mid-2017.

We believe that measuring the blood level of NGDF will provide a new way to diagnose neurodegenerative diseases accurately
at earlier stages and to monitor disease progression and treatment response.
The humanized NGDF-antibody is in the process development stage. The main therapeutic goal is to counteract
the neurodegenerative effect of diseases such as Alzheimer`s (AD), Parkinson’s (AD) diseases, and Amyotrophic
lateral sclerosis (ALS) and to aid in memory recovery and wound in healing in CNS injuries such as Stroke.
  1. ① Alzheimer`s Disease: AD is a neurodegenerative disorder characterized by progressive loss of memory and other cognitive functions. It is an incurable disease with a long, progressive period of decline that results in patients dying in a completely helpless state. All drugs approved by the US Food and Drug Administration (FDA) for the treatment of AD are symptomatic therapies that help to treat the symptoms but don’t stop the disease progression.
  2. ② Amyotrophic Lateral Sclerosis: ALS is a progressive neurodegenerative disease caused by the degeneration of motor neurons in the brain and spinal cord. Because of the loss of motor neurons, muscles atrophy leading to the paralysis of voluntary muscles. ALS is incurable and fatal, with a median survival of 3 years, and the only FDA approved drug, Riluzole provides limited benefit in life-span and quality of life.
Principally, the INSF antibody is being assessed for its ability to treat neuropathic pain. Additionally, it is also
being tested for therapeutic benefits in various animal models of motor neuron related and psychiatric disorders,
such as epilepsy, schizophrenia and autism as well.
  1. ① Neuropathic pain: Neuropathic pain is a symptom associated with peripheral nerve damage such as a traumatic injury, diabetes or infections. The physiological processes involved in moderating pain sensation can be quite complex. Unfortunately, subsequent to some injuries pain may persist even after the initial injury might have healed. Only 40-60% of patients gain partial relief by current medications, namely anti-convulsants and opioid analgesics.